Anti-phospho-PLEKHS1 (pY248) antibody
An antibody raised against PLEKHS1 phosphorylated tyrosine; a biomarker for numerous cancers and an indicator of a poor outcome.
Catalogue number crb2005329 Antibody Anti-phospho-PLEKHS1 (pY248) antibody Antigen Peptide KLH conjugated synthetic peptide crb1200565 Protein ID UniProtKB: Q5SXH7 Aliases Pleckstrin homology domain-containing family S member 1, PH domain-containing family S member 1, Epididymis luminal protein 185 (hEL185), Epididymis Secretory Sperm Binding Protein, C10orf81 Cross-Reactivity Human Target Protein Species Human Host Species Anti-Rabbit Antibody Type Polyclonal Concentration M64 0.4 mg/ml, M65 0.5 mg/ml Validation ELISA (1:1000) Target phosphorylated PLEKHS1 (pY248) Storage Stabilisers The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Specificity Protein Post-translational Modification Phosphorylation Storage The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References
Jung (2021). Dissecting the function and interactome of plekhs1 in prostate tumorigenesis (Doctoral thesis). DOI: 10.17863/CAM.63289.
Xing et al., (2020). PLEKHS1 over-expression is associated with metastases and poor outcomes in papillary thyroid carcinoma. Cancers, 12(8): 2133. DOI: 10.3390/cancers12082133.
Pleckstrin homology domain-containing family S member 1 (PLEKHS1) interaction with PI3K depends on PLEKHS1 phosphorylation to activate PI3K signalling. Mutations to the PI3K pathway are strongly linked to cancer cell progression, including prostate, thyroid and bladder. PLEKHS1 promoter mutations were identified in several cancers. PLEKHS1 promotes the aggressive behaviour of cancer cells by increasing AKT activity. Over-expression of PLEKHS1 is correlated to poor outcomes for a broad range of cancers.
PLEKHS1 may also have a role in mild hyperglycaemia with obesity.